Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Hopkins

Showing results (91-100 of 95) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 95 results.
Bioorganic & Medicinal Chemistry|July 27, 2021
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitorsBrian T Hopkins, Eris Bame, Noah Bell, et al.
Journal of Medicinal Chemistry|April 7, 2026
Leveraging Kinase Drugs for Neurosciences: Discovery of Selective, CNS-Penetrant Reversible Bruton's Tyrosine Kinase Inhibitors as Therapeutics for NeuroinflammationBrian T Hopkins, Isaac E Marx, Harlod George Vandeveer, et al.
Clinical & Translational Immunology|June 18, 2021
Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cellsEris Bame, Hao Tang, Jeremy C Burns, et al.
Journal of Medicinal Chemistry|November 4, 2021
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple SclerosisBrian T Hopkins, Eris Bame, Bekim Bajrami, et al.
Journal of Medicinal Chemistry|May 7, 2024
Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple SclerosisMartin K Himmelbauer, Bekim Bajrami, Rebecca Basile, et al.
Pageof 10

Showing results (91-100 of 95) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 95 results.
Bioorganic & Medicinal Chemistry|July 27, 2021
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitorsBrian T Hopkins, Eris Bame, Noah Bell, et al.
Journal of Medicinal Chemistry|April 7, 2026
Leveraging Kinase Drugs for Neurosciences: Discovery of Selective, CNS-Penetrant Reversible Bruton's Tyrosine Kinase Inhibitors as Therapeutics for NeuroinflammationBrian T Hopkins, Isaac E Marx, Harlod George Vandeveer, et al.
Clinical & Translational Immunology|June 18, 2021
Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cellsEris Bame, Hao Tang, Jeremy C Burns, et al.
Journal of Medicinal Chemistry|November 4, 2021
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple SclerosisBrian T Hopkins, Eris Bame, Bekim Bajrami, et al.
Journal of Medicinal Chemistry|May 7, 2024
Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple SclerosisMartin K Himmelbauer, Bekim Bajrami, Rebecca Basile, et al.
Pageof 10